Pulse Biosciences, Inc (PLSE) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $25.86: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.
Pulse Biosciences develops nanosecond Pulsed-Field Ablation (nsPFA) technology via its nPulse System, targeting atrial fibrillation treatment (cardiac surgical clamp with IDE approved; cardiac catheter IDE approved December 2025) and soft tissue ablation (Vybrance percutaneous... Read more
Sell if holding. Engine safety override at $25.86: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.2/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 60d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Pulse Biosciences, Inc
Latest news
- NEWS Canaccord Genuity Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $32 — benzinga Jun 4, 2026 positive
- NEWS Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program — benzinga May 12, 2026 positive
- NEWS Earnings Scheduled For May 4, 2026 — benzinga May 4, 2026 neutral
- NEWS Reported Saturday, Pulse Biosciences' nPulse Cardiac Catheter System Delivers 90% Kaplan-Meier Freedom From AF At One Ye — benzinga Apr 27, 2026 positive
- NEWS Pulse Biosciences Appoints Liane Teplitsky As Chief Operating Officer And Dr. David Kenigsberg As Chief Medical Officer — benzinga Apr 9, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $25.86: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.24. Score 4.2/10, moderate confidence.
Take-profit target: $26.07 (0.0% upside). Prior stop was $24.24. Stop-loss: $24.24.
Target reached (0.0% upside); Quality below floor (2.1 < 4.0).
Pulse Biosciences, Inc trades at a P/E of N/A (forward -22.4). TrendMatrix value score: 5.0/10. Verdict: Sell.
8 analysts cover PLSE with a consensus score of 4.3/5. Average price target: $31.
What does Pulse Biosciences, Inc do?Pulse Biosciences develops nanosecond Pulsed-Field Ablation (nsPFA) technology via its nPulse System, targeting atrial...
Pulse Biosciences develops nanosecond Pulsed-Field Ablation (nsPFA) technology via its nPulse System, targeting atrial fibrillation treatment (cardiac surgical clamp with IDE approved; cardiac catheter IDE approved December 2025) and soft tissue ablation (Vybrance percutaneous electrode with 510(k) clearance). The company has minimal revenue; it began the PRECISE BTN thyroid clinical trial in September 2025 and received cardiac surgical IDE approval in September 2025.